Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04781972 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

StatusRecruiting
PhasePhase 4
Started2021-07-27
View on ClinicalTrials.gov ↗

Amendment history

2025-10-15
Study Status v12
Primary completion date2026-05-01→2028-11-30
Completion date2026-05-01→2029-04-30
2025-05-06
Study Status v11
Primary completion date2025-05-01→2026-05-01
Completion date2025-05-01→2026-05-01
2024-05-15
Study Status, Sponsor/Collaborators v10
Primary completion date2024-05-01→2025-05-01
Completion date2024-05-01→2025-05-01
Collaborators+35 characters
National Institutes of Health (NIH)
2024-01-26
Study Status, Eligibility v9
Re-verified, no change to tracked fields
2023-05-12
Study Status v8
Primary completion date2023-05-01→2024-05-01
Completion date2023-05-01→2024-05-01
Show 7 earlier versions
2022-10-06
Study Status, Eligibility v7
Re-verified, no change to tracked fields
2022-05-12
Study Status v6
Primary completion date2022-05-01→2023-05-01
Completion date2022-05-01→2023-05-01
2022-01-04
Study Status, Contacts/Locations v5
Study sitescontacts updated at 1 of 1 site
2021-08-19
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2021-06→confirmed 2021-07-27
Study sites0→1
2021-05-28
Study Status v3
Start date2021-06-01→2021-06
2021-05-07
Study Status v2
Start date2021-05-01→2021-06-01
2021-04-12
Study Status v1
Primary completion date2022-04-01→2022-05-01
Completion date2022-04-01→2022-05-01
Start date2021-04-01→2021-05-01
2021-03-01
Original filing
Johns Hopkins University
505 trials monitored
See 47 trials at risk
ADHD
385 trials monitored
See 19 trials at risk
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Trial Details
NCT Number NCT04781972
Lead Sponsor Johns Hopkins University
Collaborators: National Institutes of Health (NIH)
Conditions ADHD - Combined Type
Enrollment 30 participants
Start Date 2021-07-27
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-16